Cellular Oncology

, Volume 37, Issue 4, pp 289–296 | Cite as

ARID3B expression in primary breast cancers and breast cancer-derived cell lines

  • Ayse Selcen Oguz Erdogan
  • Nihan Ozdemirler
  • Merve Oyken
  • Murat Alper
  • Ayse Elif Erson-BensanEmail author
Original Paper



ARID3B (AT-rich interaction domain 3) is a member of the family of ARID proteins, which constitutes evolutionarily conserved transcription factors implicated in normal development, differentiation, cell cycle regulation and chromatin remodeling. In addition, ARID3B has been linked to cellular immortalization, epithelial-mesenchymal transition (EMT) and tumorigenesis. Given the emerging role of ARID3B in tumor development, we examined its expression in primary patient-derived breast cancer samples and breast cancer-derived cell lines.


Immunohistochemistry (IHC) was used to detect ARID3B expression in 63 formalin-fixed paraffin-embedded (FFPE) invasive breast cancer samples. In addition, a panel of 6 (estrogen receptor-positive and -negative, ERBB2-positive and -negative) breast cancer-derived cell lines and immortalized non-tumorigenic epithelial breast cells were used for ARID3B expression analysis using RT-PCR. Specific primers and Western blotting were used to detect ARID3B isoforms.


Using IHC, nuclear, cytoplasmic and low levels of membranous ARID3B staining were detected in all 63 primary invasive breast tumors. Nuclear ARID3B staining positively correlated with estrogen receptor (ER) status and negatively correlated with tumor grade, mitotic index and ERBB2 status of the patients. Increased nuclear expression of ARID3B was confirmed in breast cancer-derived cell lines expressing ERα. In addition, two out of three ERBB2-positive breast cancer cell lines were found to lack full length ARID3B. Three ARID3B isoforms were found to be present in normal breast epithelial cells as well as in breast cancer cells.


We report a positive correlation between ER positivity and nuclear ARID3B expression in primary breast cancers, along with a negative correlation with the ERBB2 status. Very similar correlations were noted in breast cancer-derived cell lines. Since in the recent past ARID3B expression has increasingly been related to cancer-associated proteins and microRNAs, knowledge on ARID3B expression and function may be instrumental for gaining further insight into potentially important cancer-related networks.


ARID3B expression Breast cancer Estrogen receptor ERBB2 



Orta Dogu Teknik Universitesi (ODTU-METU) and Diskapi Yildirim Beyazit Training and Research Hospital scientific research funds were used throughout the study.

Conflict of interest

Authors have no conflict of interest to declare.

Supplementary material

13402_2014_185_MOESM1_ESM.pdf (683 kb)
ESM 1 (PDF 682 kb)


  1. 1.
    D. Wilsker, A. Patsialou, P.B. Dallas, E. Moran, ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 13, 95–106 (2002)PubMedGoogle Scholar
  2. 2.
    C. Lin, W. Song, X. Bi, J. Zhao, Z. Huang, Z. Li, J. Zhou, J. Cai, H. Zhao, Recent advances in the ARID family: focusing on roles in human cancer. Oncol. Targets Ther. 7, 315–324 (2014)Google Scholar
  3. 3.
    S. Numata, P.P. Claudio, C. Dean, A. Giordano, C.M. Croce, Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Res. 59, 3741–3747 (1999)PubMedGoogle Scholar
  4. 4.
    K. Kobayashi, T. Era, A. Takebe, L.M. Jakt, S. Nishikawa, ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res. 66, 8331–8336 (2006)PubMedCrossRefGoogle Scholar
  5. 5.
    J.C. Casanova, V. Uribe, C. Badia-Careaga, G. Giovinazzo, M. Torres, J.J. Sanz-Ezquerro, Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements. Development 138, 1195–1205 (2011)PubMedCrossRefGoogle Scholar
  6. 6.
    P.L. Magoulas, A.W. El-Hattab, Chromosome 15q24 microdeletion syndrome. Orphanet J. Rare Dis. 7, 2 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    K.D. Cowden Dahl, R. Dahl, J.N. Kruichak, L.G. Hudson, The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11, 1208–1215 (2009)PubMedCentralPubMedGoogle Scholar
  8. 8.
    S. Akhavantabasi, A. Sapmaz, S. Tuna, A.E. Erson-Bensan, miR-125b targets ARID3B in breast cancer cells. Cell Struct. Funct. 37, 27–38 (2009)CrossRefGoogle Scholar
  9. 9.
    A. Erson, E. Petty, miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol. Ther. 8, 2317–2322 (2009)PubMedCrossRefGoogle Scholar
  10. 10.
    R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. (Dordr.) 36, 1–7 (2013)CrossRefGoogle Scholar
  11. 11.
    E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention. Cell. Oncol. (Dordr.) 37, 167–178 (2014)CrossRefGoogle Scholar
  12. 12.
    S. Garritano, A. Inga, F. Gemignani, S. Landi, More targets, more pathways and more clues for mutant p53. Oncogenesis 2, e54 (2013)PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    K. Kobayashi, L.M. Jakt, S.I. Nishikawa, Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn. Oncogene 32, 2640–2648 (2013)PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    S. Joseph, V.E. Deneke, K.D. Cowden Dahl, ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death. PLoS One 7, e42159 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    B.H. Akman, T. Can, A.E. Erson-Bensan, Estrogen-induced upregulation and 3′-UTR shortening of CDC6. Nucleic Acids Res. 40, 10679–10688 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    S. Akhavantabasi, H.B. Akman, A. Sapmaz, J. Keller, E.M. Petty, A.E. Erson, USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm. Genome 21, 388–397 (2010)PubMedCrossRefGoogle Scholar
  17. 17.
    W.J. Kent, C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler, D. Haussler, The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002)PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    R. Metivier, G. Penot, R.P. Carmouche, M.R. Hubner, G. Reid, S. Denger, D. Manu, H. Brand, M. Kos, V. Benes, F. Gannon, Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J. 23, 3653–3666 (2004)PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    D. McDonald, G. Carrero, C. Andrin, G. de Vries, M.J. Hendzel, Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations. J. Cell Biol. 172, 541–552 (2006)PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, S.L. Deming, J. Geradts, M.C. Cheang, T.O. Nielsen, P.G. Moorman, H.S. Earp, R.C. Millikan, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006)PubMedCrossRefGoogle Scholar
  21. 21.
    G. Scott, A. Goga, D. Bhaumik, C. Berger, C. Sullivan, C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–1486 (2007)PubMedCrossRefGoogle Scholar
  22. 22.
    S.J. Samyesudhas, L. Roy, K.D. Cowden Dahl, Differential expression of ARID3B in normal adult tissue and carcinomas. Gene 10, 174–180 (2014)CrossRefGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2014

Authors and Affiliations

  • Ayse Selcen Oguz Erdogan
    • 1
    • 2
  • Nihan Ozdemirler
    • 1
  • Merve Oyken
    • 1
  • Murat Alper
    • 2
  • Ayse Elif Erson-Bensan
    • 1
    Email author
  1. 1.Department of Biological SciencesMETUAnkaraTurkey
  2. 2.Department of PathologyDiskapi Yildirim Beyazit Training and Research HospitalAnkaraTurkey

Personalised recommendations